Is atherosclerosis an infectious disease?

Cleveland Clinic Journal of Medicine

Volumn 68, Issue 5, 2001, Pages 449-458

  Mawhorter, Steven D ^b   Lauer, Michael A ^a  

^a BORGESS MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; C REACTIVE PROTEIN; FIBRINOGEN; GATIFLOXACIN; MACROLIDE; METRONIDAZOLE; OMEPRAZOLE; ROXITHROMYCIN;

ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CYTOMEGALOVIRUS; HEART INFARCTION; HELICOBACTER PYLORI; HUMAN; INFLAMMATION; MONOCYTE; NONHUMAN; REVIEW; RISK FACTOR; SECONDARY PREVENTION; T LYMPHOCYTE; VIRUS INFECTION;

EID: 0035002658     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.68.5.449     Document Type: Review

References (72)

1. Braunwald E. Shattuck lecture - Cardiovascular medicine at the turn of the millennium; triumphs, concerns, and opportunities. N Engl J Med 1997; 337:1360-1369.
2. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340:115-126.
3. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336:973-979.
4. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91:2844-2850.
5. Epstein SE, Zhou YF, Zhu J. Infections and atherosclerosis: emerging mechanistic paradigms. Circulation (Online) 1999; 100:e20-e28.
6. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997; 350:430-436.
7. Nieto FJ. Infections and atherosclerosis: new clues from an old hypothesis? Am J Epidemiol 1998; 148:937-948.
8. Ellis RW. Infection and coronary heart disease. J Med Microbiol 1997; 46:535-539.
9. Virchow R. Cellular pathology as based upon physiological and pathological histology. (English translation of second German edition). Philadelphia, PA: JB Lippincott, 1971.
10. Osler W. Diseases of the arteries. In: Osier W, MacCrae T, editors. Modern Medicine. Its Theory and Practice in Original Contributions by Americans and Foreign Authors. Vol 4. Philadelphia, PA: Lea & Fabiger, 1908:426-427.
11. 4-infected mice. Lab Invest 1968; 19:399-405.
12. Nichols AC, Thomas M. Coxsackie virus infection in acute myocardial infarction. Lancet 1977; 1:883-884.
13. Wood SF, Rogen AS, Bell EJ, Grist NR. Role of Coxsackie B viruses in myocardial infarction. Br Heart J 1978; 40:523-525.
14. O'Neill D, McArthur JD, Kennedy JA, Clements G. Coxsackie B virus infection in coronary care unit patients. J Clin Pathol 1983; 36:658-661.
15. Minick CR, Fabricant CG, Fabricant J, Litrenta MM. Atheroarteriosclerosis induced by infection with herpesvirus. Am J Pathol 1979; 96:673-706.
16. Fabricant CG, Fabricant J, Minick CR, Litrenta MM. Herpesvirus-induced atherosclerosis in chickens. Fed Proc 1983; 42:2476-2479.
17. Yamashiroya HM, Ghosh L, Yang R, Robertson AL. Herpesviridae in the coronary arteries and aorta of young trauma victims. Am J Pathol 1988; 130:71-79.
18. Gyorkey F, Melnick JL, Guinn GA, Gyorkey P, DeBakey ME. Herpesvirus in the endothelial and smooth muscle cells of the proximal aorta in arteriosclerotic patients. Exp Mol Pathol 1984; 40:328-339.
19. Hajjar DP, Pomerantz KB, Falcone DJ, Weksler BB, Grant AJ. Herpes simplex virus infection in human arterial cells: implications in atherosclerosis. J Clin Invest 1987; 80:1317-1321.
20. Melnick JL, Petrie BL, Dreesman GR, Burek J, McCollum CH, DeBakey ME. Cytomegalovirus antigen within human arterial smooth muscle cells. Lancet 1983; 2:644-647.
21. Zhou YF, Leon MB, Waclawiw MA, Popma JJ, Yu ZX, Finkel T, Epstein SE. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med 1996; 335:624-630.
22. Speir D, Modali R, Huang E-S, et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 1994; 265:391-394.
23. Benditt EP, Benditt JM. Evidence for a monoclonal origin of human atherosclerotic plaques. Proc Natl Acad Sci USA 1973; 70:1753-1756.
24. Manegold C, Alwazzeh M, Jablonowski H, et al. Prior CMV infection and the risk or restenosis after PTCA. Circulation 1999; 99:1290-1294.
25. Kol A, Sperti G, Shani J, et al. Cytomegalovirus replication is not a cause of instability in unstable angina. Circulation 1995; 91:1910-1913.
26. Adler SP, Hur JK, Wang JB, et al. Prior infection with cytomegalovirus is not a major risk factor for angiographically demonstrated coronary artery atherosclerosis. J Infect Dis 1998; 177:209-212.
27. Muhlestein JB, Carlquist JF, Home BD, King GJ, Elmer SP, Anderson JL. No association between prior cytomegalovirus infection and the risk of clinical restenosis after percutaneous coronary interventions [abstract]. Circulation 1997; 96(suppl 1):1-650.
28. Ventura HO, Mehra MR, Smart FW, Stapleton DD. Cardiac allograft vasculopathy: current concepts. Am Heart J 1995; 129:791-798.
29. Valantine HA, Gao SZ, Menon SG, et al. Impact of prophylactic immediate post-transplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 1999; 100:61-66.
30. Grayston JT. Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J Infect Dis 2000; 181(suppl 3):S402-S410.
31. Wang S-P, Grayston JT. Population prevalence of antibody to Chlamydia pneumoniae strain TWAR. In: Bowie WR, Caldwell HD, Jones RP, et al, editors. Chlamydial Infections. Cambridge, Cambridge University Press. 1990:402-405.
32. Saikku P, Mattila K, Nieminen MS, et al. Serological evidence of an association of a novel chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2:983-986.
33. Kuo C-C, Shor A, Campbell LA, Fukushi A, Patton DL, Grayston JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993, 167:841-849.
34. Wang S-P, Grayston JT. Population prevalence of antibody to Chlamydia pneumoniae strain TWAR. In: Bowie WR, Caldwell HD, Jones RP et al, editors. Chlamydial infections. Cambridge, UK: Cambridge University Press; 1990: 402-405.
35. Muhlestein JB, Hammond EH, Carlquist JF, et al. Increased incidence of chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol 1996; 27:1555-1561.
36. Starr JR, Jackson LA. Chlamydia pneumoniae and atherosclerotic cardiovascular disease. Clin Micro News 1999; 21:145-148.
37. Gibbs RGJ, Carey N, Davies AH. Chlamydia pneumoniae and vascular disease. Br J Surg 1998; 85:1191-1197.
38. Jackson LA, Campbell LA, Kuo OC,Rodriguez DI, Lee A, Gayston JT. Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis 1997; 176:292-295.
39. Maass M, Bartels C, Engel PM, Mamat U, Sievers HH. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol 1998; 31:827-832.
40. Jackson LA, Campbell LA, Schmidt RA, et al. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis. Am J Pathol 1997; 150:1785-1790.
41. Gaydos CA, Summersgill JT, Sahney NN, Ramirez JA, Quinn TC. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immunol 1996; 64:1614-1620.
42. Godzik KL, O'Brien ER, Wang S, Kuo C. In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae. J Clin Microbiol 1995; 33:2411-2414.
43. Maass M, Jahn J, Gieffers J, et al. Detection of Chlamydia pneumoniae within peripheral blood monocytes of patients with unstable angina or myocardial infarction. J Infect Dis 2000; 181(suppl 3):S449-S451.
44. Boman J, Gaydos CA. Polymerase chain reaction detection of Chlamydia pneumoniae in circulating white blood cells. J Infect Dis 2000; 181(suppl 3):S452-S454.
45. Gupta S, Camm AJ. Chronic infection in the etiology of atherosclerosis - the case for C. pneumoniae. Clin Cardiol 1997; 20:829-836.
46. Moazed TC, Kuo CC, Grayston JT, Campbell LA. Evidence of systemic dissemination of Chlamydia pneumoniae via macrophages in the mouse. J Infect Dis 1998; 177:1322-1325.
47. Taylor-Robinson D, Thomas BJ. Chlamydia pneumoniae in atherosclerotic tissue. J Infect Dis 2000; 181(suppl 3):S437-S440.
48. Kuo CC, Graystone JT, Campbell LA, et al. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15 to 35 years old). Proc Natl Acad Sci USA 1995; 92(15):6811-6814.
49. Fong IW, Chiu B, Viira E, et al. Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol 1997; 35:48-52.
50. Muhlestein JB, Anderson JL, Hammond ZH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998; 97:633-636.
51. Ramirez JA, Chlamydia pneumoniae/Atherosclerosis study group. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. Ann Intern Med 1996; 125:979-982.
52. Rosenfeld MZ, Morzed TC, Ricks J, Campbell LA, Kyo C. Chronic infection with Chlamydia pneumoniae accelerates atherosclerosis in apolipoprotein E deficient mice. Circulation 1998; 97:633-636.
53. Laitmen K, Laurila A, Pyhala L, Leinonen M, Saikku P, Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect Immunol 1997; 65:4832-4835.
54. Kalayoglu MV, Byrne GI. Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis 1998; 177:725-729.
55. Mendall MA, Goggin PM, Molineaux N, et al. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 1994; 71:437-439.
56. Malaty HM, Graham DY. Importance of childhood socio-economic status on the current prevalence of Helicobacter pylori infection. Gut 1994; 35:742-745.
57. Lynch JW, Kaplan GA, Cohen RD, et al. Do cardiovascular risk factors explain the relation between socioeconomic status, risk of all-cause mortality, cardiovascular mortality, and acute myocardial infarction? Am J Epidemiol 1996; 144:934-942.
58. Torgano G, Cosentini R, Mandelli C, et al. Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease. Circulation 1999; 99:1555-1559.
59. Anderson JL, Carlquist FJ, Muhlestein JB, et al. Evaluation of CRP, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. J Am Coll Cardiol 1998; 32:35-41.
60. Mackenzie RS, Millard HD. Interrelated effects of diabetes, arteriosclerosis, and calculus on alveolar bone loss. J Am Dent Assoc 1963; 66:192-198.
61. Beck J, Garcia R, Heiss G, Vokonas P, Oftenbacher S. Periodontal disease and cardiovascular disease. J Periodont 1996; 67:1123-1137.
62. Deshpande RG, Khan MB, Genco CA. Invasion of aortic and heart endothelial cells by Porphyromonas gingivalis. Infect Immun 1998; 66:5337-5343.
63. Gupta S, Leatham EW, Carrington D, et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96:404-407.
64. Anderson JL, Muhlestein JB, Carlquist J, et al. Randomized Secondary Prevention Trial of Azithromycin in Patients with Coronary Artery Disease and Serological Evidence for Chlamydia pneumoniae Infection. The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) Study. Circulation 1999; 99:1540-1547.
65. Garfinkel E, Bozovich G, Daroca A, et al. Randomized trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet 1997; 350:404-407.
66. Agen C, Danesi R, Blandizzi C, et al. Macrolide antibiotics as anti-inflammatory agents: roxithromycin in an unexpected role. Agents Actions 1993; 38:85-90.
67. Kita E, Sawaki M, Mikasa K, et al. Alterations of host response by a long-term treatment of roxithromycin. J Antimicrob Chemother 1993; 32:285-294.
68. Morikawa K, Oseko F, Morikawa S, Iwamoto K. Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. Antimicrob Agents Chemother 1994; 38:2643-2647.
69. Morikawa K, Wataba H, Araake M, Morikawa S. Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Antimicrobl Agents Chemother 1996; 40:1366-1370.
70. Hammerschlag MR, Chirgwin K, Roblin PM, et al. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis 1992; 14:178-182.
71. Meier, CR, Derby LE, Jick SS, et al. Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA 1999; 281:427-431.
72. Jackson LA, Smith NL, Heckbert SR, et al. Lack of association between first myocardial infarction and past use of erythromycin, tetracycline, or doxycycline. Emerg Infect Dis 1999; 5:281-284.